HUP0102459A2 - Szubsztituált szulfonil-cianamidok, eljárás az előállításukra és gyógyszerkénti alkalmazásuk - Google Patents
Szubsztituált szulfonil-cianamidok, eljárás az előállításukra és gyógyszerkénti alkalmazásukInfo
- Publication number
- HUP0102459A2 HUP0102459A2 HU0102459A HUP0102459A HUP0102459A2 HU P0102459 A2 HUP0102459 A2 HU P0102459A2 HU 0102459 A HU0102459 A HU 0102459A HU P0102459 A HUP0102459 A HU P0102459A HU P0102459 A2 HUP0102459 A2 HU P0102459A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- hydrogen atom
- alkyl group
- formula
- carbon atoms
- Prior art date
Links
- -1 sulphonyl cyanamides Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 4
- 229910052794 bromium Inorganic materials 0.000 abstract 4
- 229910052801 chlorine Inorganic materials 0.000 abstract 4
- 239000000460 chlorine Substances 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 4
- 239000011737 fluorine Substances 0.000 abstract 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052740 iodine Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 150000001805 chlorine compounds Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
A találmány (I) általános képletű vegyületekre vonatkozik, amelyekképletében a szimbólumok jelentése az alábbiakban megadott. Avegyületek a nátriumfüggő bikarbonát/klorid cseremechanizmustgátolják, ezért számos betegség kezelésére és megelőzésérealkalmazhatók, például szívinfarktus, angina pectoris, ischaemiaokozta megbetegedések, szívischaemia, valamint olyan betegségek,amelyeknek a sejtproliferáció az első vagy a másodlagos oka. Avegyületek sebészeti célú transzplantátumok konzerválásában éstárolásában is alkalmazhatók. X jelentése (a), (b) vagy (c) általánosképletű csoport, R13, R14 és R15 jelentése egymástól függetlenülhidrogénatom, 1-8 szénatomos alkilcsoport, fluor-, klór-, bróm-,jódatom, trifluor-metil-, ciano-, nitrocsoport, SOq-R79, -CO-R80 vagy-O-R81 képletű csoport, ahol q értéke egymástól függetlenül 0, 1 vagy2, R79 jelentése 1-8 szénatomos alkilcsoport vagy fenilcsoport, amelyszubsztituálatlan vagy egyszeresen, kétszeresen vagy háromszorosan,azonosan vagy eltérően szubsztituált fluor-, klór-, bróm-, jódatommal,trifluor-metil-, metil-, metoxi-, hidroxilcsoporttal és/vagy -NR82R83képletű csoporttal, amelyben R82 és R83 egymástól függetlenülhidrogénatomot vagy 1-4 szénatomos alkilcsoportot jelent, R80jelentése hidrogénatom, 1-8 szénatomos alkilcsoport vagy -OR84 képletűcsoport, ahol R84 hidrogénatomot vagy 1-8 szénatomos alkilcsoportotjelent, R81 jelentése hidrogénatom, 1-8 szénatomos alkilcsoport vagyfenilcsoport, amely szubsztituálatlan vagy egyszeresen, kétszeresenvagy háromszorosan, azonosan vagy eltérően szubsztituált fluor-,klór-, bróm-, jódatommal, trifluor-metil-, metil-, metoxi-,hidroxilcsoporttal és/vagy -NR82R83 képletű csoporttal; Y jelentéseCR16R17, CO, S, SO2, O vagy NR18, R16 jelentése hidrogénatom vagy -OR85 képletű csoport, R85 jelentése hidrogénatom, 1-8 szénatomosalkilcsoport vagy -COR86 képletű csoport, ahol R86 jelentése 1-8szénatomos alkilcsoport vagy fenilcsoport, amely szubsztituálatlanvagy egyszeresen, kétszeresen vagy háromszorosan, azonosan vagyeltérően szubsztituált fluor-, klór-, bróm-, jódatommal, trifluor-metil-, metil-, metoxi- és/vagy hidroxilcsoporttal, R17 jelentésehidrogénatom vagy 1-8 szénatomos alkilcsoport, R18 jelentésehidrogénatom, 1-8 szénatomos alkilcsoport, -CO-R87 vagy SO2R88 képletűcsoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19820064A DE19820064A1 (de) | 1998-05-06 | 1998-05-06 | Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| PCT/EP1999/002940 WO1999057102A1 (de) | 1998-05-06 | 1999-04-30 | Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0102459A2 true HUP0102459A2 (hu) | 2002-03-28 |
| HUP0102459A3 HUP0102459A3 (en) | 2002-12-28 |
| HU225377B1 HU225377B1 (en) | 2006-10-28 |
Family
ID=7866747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102459A HU225377B1 (en) | 1998-05-06 | 1999-04-30 | Substituted sulphonyl cyanamides, their use and pharmaceutical compositions containing them |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6573288B1 (hu) |
| EP (1) | EP1076651B1 (hu) |
| JP (1) | JP4546644B2 (hu) |
| KR (1) | KR20010043304A (hu) |
| CN (1) | CN1177829C (hu) |
| AR (1) | AR016255A1 (hu) |
| AT (1) | ATE293606T1 (hu) |
| AU (1) | AU756844B2 (hu) |
| BR (1) | BR9911009A (hu) |
| CA (1) | CA2331863A1 (hu) |
| DE (3) | DE19820064A1 (hu) |
| DK (1) | DK1076651T3 (hu) |
| ES (1) | ES2241326T3 (hu) |
| HK (1) | HK1038008A1 (hu) |
| HR (1) | HRP20000746A2 (hu) |
| HU (1) | HU225377B1 (hu) |
| ID (1) | ID28020A (hu) |
| IL (1) | IL139264A (hu) |
| NO (1) | NO317886B1 (hu) |
| NZ (1) | NZ507964A (hu) |
| PL (1) | PL344041A1 (hu) |
| PT (1) | PT1076651E (hu) |
| RU (1) | RU2221789C2 (hu) |
| SK (1) | SK16582000A3 (hu) |
| TR (1) | TR200003248T2 (hu) |
| WO (1) | WO1999057102A1 (hu) |
| ZA (1) | ZA200006166B (hu) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220383A1 (en) * | 2002-02-14 | 2003-11-27 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders |
| DE10206354A1 (de) * | 2002-02-14 | 2003-08-28 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen |
| ITTO20060575A1 (it) * | 2006-08-02 | 2008-02-03 | Univ Pisa | Inibitori di zinco proteinasi tioaril sostituiti e loro usi |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| IL98319A (en) * | 1990-07-05 | 1997-04-15 | Roussel Uclaf | Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them |
| US5126342A (en) * | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
| CA2058198A1 (en) * | 1991-01-04 | 1992-07-05 | Adalbert Wagner | Azole derivatives, process for their preparation, and their use |
| TW215434B (hu) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
| US5310929A (en) * | 1992-08-06 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
| FR2711368B1 (fr) * | 1993-09-16 | 1996-01-05 | Roussel Uclaf | Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus. |
| FR2716883B1 (fr) * | 1994-03-04 | 1996-04-26 | Roussel Uclaf | Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant. |
| DE19540995A1 (de) * | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| EP0855392A3 (de) * | 1997-01-22 | 2000-01-05 | Hoechst Aktiengesellschaft | Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19741635A1 (de) * | 1997-09-22 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE19804251A1 (de) | 1998-02-04 | 1999-08-05 | Hoechst Marion Roussel De Gmbh | Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
-
1998
- 1998-05-06 DE DE19820064A patent/DE19820064A1/de not_active Withdrawn
-
1999
- 1999-04-30 CN CNB998073148A patent/CN1177829C/zh not_active Expired - Fee Related
- 1999-04-30 AU AU59479/99A patent/AU756844B2/en not_active Ceased
- 1999-04-30 WO PCT/EP1999/002940 patent/WO1999057102A1/de not_active Application Discontinuation
- 1999-04-30 HU HU0102459A patent/HU225377B1/hu not_active IP Right Cessation
- 1999-04-30 CA CA002331863A patent/CA2331863A1/en not_active Abandoned
- 1999-04-30 KR KR1020007012268A patent/KR20010043304A/ko not_active Application Discontinuation
- 1999-04-30 JP JP2000547072A patent/JP4546644B2/ja not_active Expired - Fee Related
- 1999-04-30 TR TR2000/03248T patent/TR200003248T2/xx unknown
- 1999-04-30 EP EP99948554A patent/EP1076651B1/de not_active Expired - Lifetime
- 1999-04-30 SK SK1658-2000A patent/SK16582000A3/sk unknown
- 1999-04-30 DE DE19980787T patent/DE19980787D2/de not_active Expired - Lifetime
- 1999-04-30 DE DE59911949T patent/DE59911949D1/de not_active Expired - Lifetime
- 1999-04-30 ES ES99948554T patent/ES2241326T3/es not_active Expired - Lifetime
- 1999-04-30 PT PT99948554T patent/PT1076651E/pt unknown
- 1999-04-30 NZ NZ507964A patent/NZ507964A/xx unknown
- 1999-04-30 US US09/674,606 patent/US6573288B1/en not_active Expired - Lifetime
- 1999-04-30 ID IDW20002257A patent/ID28020A/id unknown
- 1999-04-30 BR BR9911009-1A patent/BR9911009A/pt not_active IP Right Cessation
- 1999-04-30 IL IL13926499A patent/IL139264A/en not_active IP Right Cessation
- 1999-04-30 PL PL99344041A patent/PL344041A1/xx unknown
- 1999-04-30 DK DK99948554T patent/DK1076651T3/da active
- 1999-04-30 RU RU2000130719/04A patent/RU2221789C2/ru not_active IP Right Cessation
- 1999-04-30 AT AT99948554T patent/ATE293606T1/de not_active IP Right Cessation
- 1999-05-04 AR ARP990102087A patent/AR016255A1/es unknown
-
2000
- 2000-10-31 ZA ZA200006166A patent/ZA200006166B/xx unknown
- 2000-11-03 HR HR20000746A patent/HRP20000746A2/hr not_active Application Discontinuation
- 2000-11-03 NO NO20005549A patent/NO317886B1/no unknown
-
2001
- 2001-11-12 HK HK01107942A patent/HK1038008A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0515459A (pt) | composição herbicida | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| PE20050652A1 (es) | Mezclas que contienen estrobilurinas y moduladores de etileno | |
| RU2389719C3 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| NO20085269L (no) | 2-tioksantinderivater som fungerer som MPO-inhibitorer | |
| DK365184D0 (da) | 1,8-naphthyridinderivater eller estre eller salte deraf, deres fremstilling og anvendelse som farmaceutika | |
| BR0317094A (pt) | Sal de alumìnio livre de zircÈnio, e, composição antiperspirante | |
| HUP0000343A2 (hu) | 1,3-Propándiol-származékok alkalmazása szervátültetés után fellépő kilökődés megakadályozására | |
| EA200701035A1 (ru) | Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения | |
| JP2010524947A5 (hu) | ||
| TW200616954A (en) | N-(1h-indolyl)-1h-indole-2-carboxamide derivatives, their preparation and their application in therapeutics | |
| RU2003130751A (ru) | Способ получения 1, 3-замещенных инденов и арил-конденсированных азаполиклических соединений | |
| NO20035774L (no) | Substituerte benzopyranderivater mot arytmier | |
| HUP0102459A2 (hu) | Szubsztituált szulfonil-cianamidok, eljárás az előállításukra és gyógyszerkénti alkalmazásuk | |
| AP1555A (en) | Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance | |
| NO20055167L (no) | Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| EA199801013A1 (ru) | Производные дистамицина, способ их получения и применение в качестве противоопухолевых и противовирусных агентов | |
| BR0207644A (pt) | Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar | |
| BR0214227B1 (pt) | composiÇÕes fungicidas, uso das mesmas, e, mÉtodo para combater infecÇÕes de fungos. | |
| DE50304891D1 (de) | N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel | |
| DK0533827T3 (da) | Oxazolderivater, deres fremstilling og farmaceutiske præparater deraf | |
| ES2175405T3 (es) | Derivados de adenosina. | |
| MA27143A1 (fr) | Utilisation de derives de 2-amino-4- pyridylmethyl-thiazoline comme inhibiteurs de no-synthase inductible | |
| BR9814232A (pt) | Benzilidenopirazolona, composição, processos para a preparação de composições herbicidamente ativas, para controlar vegetação indesejada e para a preparação de benzilidenopirazolonas, e, benzoilpirazol. | |
| DK1021413T3 (da) | Fremstilling og anvendelse af ortho-sulfonamido-bicykliske heteroarylhydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |